Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
Credit: AI
A new Phase II clinical trial has found that a carefully formulated cannabis-based treatment may help alleviate agitation in people with advanced dementia. The findings offer hope for patients and caregivers who face one of the most distressing symptoms of the disease.
The findings are a result of the LiBBY (Life's End Benefits of cannaBidiol and tetrahYdrocannabinol) trial, that was presented at the Alzheimer's Association International Conference (AAIC) 2026 in London.
Researchers say the treatment, which combines purified tetrahydrocannabinol (THC) and cannabidiol (CBD) in an oral formulation, showed significant improvements compared to a placebo.
The multicenter, randomized, double-blind, placebo-controlled Phase II study enrolled 120 hospice-eligible adults with Alzheimer's disease or other forms of dementia experiencing significant agitation.
Participants received either the THC/CBD formulation or a placebo for 12 weeks. Researchers assessed agitation using the Cohen-Mansfield Agitation Inventory (CMAI) along with clinician evaluations of behavioral improvement.
According to the trial results, participants in the cannabis treatment group experienced significantly greater reductions in agitation than those given a placebo.
Clinician assessments showed improvement in 83.9% of treated participants after two weeks, compared with 30.5% in the placebo group.
By 12 weeks, improvement was seen in 87.2% of treated participants versus 23.6% receiving placebo. Nearly 90% of treated participants showed overall clinical improvement during the study.
The study's lead investigator, Dr. Jacobo Mintzer of the Medical University of South Carolina, said, "These results were extremely impressive and showed a level of response not seen before in clinical trials related to dementia. Rarely do we see close to 90% of patients in a trial respond positively to a new medication."
He added, "Agitation affects many people with late-stage dementia, causing symptoms such as restlessness, aggression, and emotional distress that can profoundly impact patients and their caregivers. Current treatment options are limited and often carry significant side effects."
Also read: Normal Ageing or Alzheimer's? Doctors Explain Six Key Differences to Watch For
Agitation affects the majority of people living with Alzheimer's disease and other dementias, especially in the advanced stages.
Symptoms may include pacing, aggression, yelling, restlessness, irritability, and emotional distress, making day-to-day care increasingly challenging.
It also places a heavy emotional and physical burden on caregivers. Many currently prescribed medications, including antipsychotics and sedatives, may increase the risk of falls, excessive sedation, stroke, or even death in older adults.
A treatment that safely reduces agitation without substantially increasing adverse events could be helpful for the patients as well as caregivers.
Investigators said that the results are the strongest seen so far in clinical trials on agitation in advanced dementia.
Also read: Alzheimer's May Be Detectable Years Before Symptoms, Says Neurology Expert
Dementia is an umbrella term describing a significant decline in mental function that interferes with everyday life. It commonly affects memory, thinking and reasoning abilities and is caused by underlying conditions such as Alzheimer's disease or vascular dementia.
Dementia significantly affects an individual's ability to live independently, work and perform daily activities while placing a substantial burden on families and caregivers.
According to the WHO, dementia costs the global economy an estimated US$1.3 trillion every year, with about half of that amount attributed to unpaid care provided by family members and friends.
Credit: X
Lionel Messi is one of the most iconic football players in the world. What many people don't realize is that his athletic career almost ended before it truly began.
As a child, Messi was diagnosed with Growth Hormone Deficiency (GHD), a rare medical condition that affects normal growth and development.
With the ongoing FIFA fever, his story has sparked renewed interest, particularly because Barcelona helped shape football history.
Growth Hormone Deficiency is a condition in which the pituitary gland does not produce enough growth hormone, a hormone essential for normal growth in children. Without adequate treatment, children with GHD often experience the following symptoms:
While growth is the most noticeable concern, modern treatment allows many children to achieve normal or near-normal adult height if diagnosed early.
Messi himself has spoken in recent interviews about the financial and emotional challenges his family faced during those years.
Doctors recommended regular treatment with synthetic growth hormone, requiring frequent injections over several years.
At the time, growth hormone therapy reportedly cost around $900 to $1,000 per month, an amount that Messi's family could not afford.
Messi's local Argentine club, Newell's Old Boys, initially provided some assistance, but not long-term financial support.
His skills on the field eventually caught the attention of FC Barcelona. The Spanish club agreed to sign the young Argentine and help cover the costs of his medical treatment.
The decision required Messi and his family to relocate from Rosario, Argentina, to Spain, which became one of the most significant turning points in football history.
This remains one of the biggest misconceptions surrounding Messi's football career. Messi received growth hormone therapy as a medically prescribed treatment, not as a performance-enhancing drug.
The treatment was meant to correct a hormone deficiency and allow normal physical development under medical supervision.
Sports medicine experts have long emphasized that therapeutic treatment for Growth Hormone Deficiency is fundamentally different from the illegal misuse of growth hormone for athletic performance.
Today, Growth Hormone Deficiency is a recognized endocrine disorder. When diagnosed early and treated appropriately, many children experience significant improvements in growth and can lead healthy, active lives.
Messi's story is more than a football success story. It underscores the importance of early diagnosis and access to specialized medical care. Pediatricians recommend evaluating children whose height or growth pace consistently falls well below expected levels for their age.
Credit: AI
The U.S. Department of Defense is introducing a new policy that will require military personnel over 30 and above to undergo an annual testosterone deficiency screening as part of their routine Periodic Health Assessment.
Personnel under 30 can choose to be screened voluntarily. Those diagnosed with testosterone deficiency may opt for testosterone replacement therapy (TRT), though treatment will remain voluntary.
Defense Secretary Pete Hegseth made the announcement on Wednesday, saying the military must ensure that troops remain physically and mentally prepared for the demands of modern warfare.
Hegseth said in a video posted on X, "As we know, the modern battlefield is brutal and unrelenting. It requires and demands maximum psychological and mental readiness. I'm authorizing a new screening program for testosterone deficiency for our service members, ensuring you have the right testosterone levels to operate at your absolute best."
"By addressing these health markers early, we're keeping you on the leading edge of lethality and giving you the same level of support that you give this nation: the absolute best."
The Defense Secretary also said the goal extends beyond active military service.
"We owe our warriors the absolute best medical care in the world. Taking care of your long-term health means ensuring you remain strong, resilient, and capable, not just for your next deployment, but for the rest of your life."
Also read: Donald Trump's 'Two Mangled Hands' Spark Fresh Health Speculation
Testosterone is a hormone that plays an important role in maintaining muscle mass, bone density, strength, energy levels, mood and sexual function in men. Levels naturally decline with age, typically beginning around age 30, falling by roughly 1% each year thereafter.
Military experts say service members may face additional risk factors like high operational tempo, chronic stress, sleep deprivation, traumatic brain injury, blast exposure, and prolonged physical exertion.
Army Major Theodore Crisostomo-Wynne, a urologist at Madigan Army Medical Center, previously told an FDA advisory panel that researchers have observed hormonal disruptions among elite military personnel.
"The high operations tempo and high stress that these service members go through can actually decrease testosterone, sometimes acutely and sometimes even in the long term," he said.
Also read: Expert Highlights Key Vitamins To Combat Male Infertility And Boost Reproductive Health
While low testosterone is a genuine medical condition, physicians caution that it should not be diagnosed or treated simply because hormone levels decline with age.
The American Urological Association says a diagnosis requires both symptoms of testosterone deficiency and at least two separate early-morning blood tests confirming low testosterone levels.
Experts also note that testosterone replacement therapy is intended for people with clinically confirmed deficiency, not healthy individuals seeking improved athletic performance or anti-aging benefits.
According to the Endocrine Society, using testosterone without a medical indication may increase the risk of acne, infertility, worsening sleep apnea, and other adverse effects.
Testosterone deficiency, also known as hypogonadism, occurs when the body does not produce enough testosterone to maintain normal bodily functions. Common symptoms of testosterone deficiency include:
A diagnosis requires both symptoms and laboratory confirmation, according to medical guidelines.
© 2024 Bennett, Coleman & Company Limited